KSI-101 has been well-tolerated 18 Asia KSI-101 pooled (N=13) Summary of AEs in the Study eye, n (%) Subjects with ≥1 AEs 3 (23.1) Treatment-related AEs 0 Serious AEs 0 Treatment-related serious AEs 0 Severe AEs 0 AEs leading to study discontinuation 0 Selected AEs in the Study Eye, n (%) Intraocular inflammation 0 Occlusive retinal vasculitis 0 Cataract 0 Dry Eye 1 (7.7) Ocular discomfort 1 (7.7) Posterior capsule opacification 1 (7.7) AE, Adverse event. Events are investigator reported. Adverse events are treatment-emergent events with start date ≥first study drug date and ≤last study drug date + 28 days. KSI-101 was safe and well tolerated. No cases of retinal vasculitis or occlusive retinal vasculitis were observed.